Background Hypermethylation of CpG islands in tumor suppressor gene plays an important role in carcinogenesis. Many studies have demonstrated that hypermethylation in promoter region of RARβ gene could be found with high prevalence in tumor tissue and autologous controls such as corresponding non-tumor lung tissue, sputum and plasma of the NSCLC patients. But with the small number subjects included in the individual studie, the statistical power is limited. Accordingly, we performed this meta-analysis to further asses the relationship of methylation prevalence between the cancer tissue and atuologous controls (corresponding non-tumor lung tissue, sputum and plasma). Methods The published articles about RARβ gene promoter hypermethyltion were identified using a systematic search strategy in PubMed, EMBASE and CNKI databases. The pooled odds ratio (OR) of RARβ promoter methylation in lung cancer tissue versus autologous controls were calculated. Results Finally, eleven articles, including 1347 tumor tissue samples and 1137 autologous controls were included in this meta-analysis. The pooled odds ratio of RARβ promoter methylation in cancer tissue was 3.60 (95%CI: 2.46–5.27) compared to autologous controls with random-effect model. Strong and significant correlation between tumor tissue and autologous controls of RARβ gene promoter hypermethylation prevalence across studies (Correlation coefficient 0.53) was found. Conclusion RARβ promoter methylation may play an important role in carcinogenesis of the NSCLC. With significant methylation prevalence correlation between tumor tissue and autologous of this gene, methylation detection may be a potential method for searching biomarker for NSCLC.
References
[1]
eSantis C, Naishadham D, Jemal A (2013) Cancer statistics for African Americans, 2013. CA Cancer J Clin 63: 151–166.
[2]
iegel R, Naishadham D, Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62: 283–298.
[3]
Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, et al. (2004) DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep 12: 177–180.
[4]
Choy MK, Movassagh M, Goh HG, Bennett MR, Down TA (2010) Genome-wide conserved consensus transcription factor binding motifs are hyper-methylated. BMC Genomics 11: 519.
[5]
Miller CA, Sweatt JD (2007) Covalent modification of DNA regulates memory formation. Neuron 53: 857–869.
[6]
El-Osta A (2003) DNMT cooperativity—the developing links between methylation, chromatin structure and cancer. Bioessays 25: 1071–1084.
[7]
Mattei MG, de The H, Mattei JF, Marchio A, Tiollais P, et al. (1988) Assignment of the human hap retinoic acid receptor RAR beta gene to the p24 band of chromosome 3. Hum Genet 80: 189–190.
[8]
Higgins JP, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions updated March 2011 John Wiley & Sons, Available: http://www.cochrane-handbook.org/.Access？ed: 2011 DEC 12.
[9]
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.) 327: 557–560.
[10]
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 315: 629–634.
[11]
Song H, Yi J, Zhang Y, Wang R, Chen L (2011) DNA methylation of tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Chinese journal of lung cancer 14: 233–238.
[12]
Zhang CY, Jin YT, Xu HY, Zhang H, Zhang WM, et al. (2011) Relationship between promoter methylation of p16, DAPK and RAR beta genes and the clinical data of non-small cell lung cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28: 23–28.
[13]
Feng Q, Hawes SE, Stern JE, Wiens L, et al. (2008) DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 17: 645–654.
[14]
Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, et al. (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110: 2019–2026.
[15]
Hsu HS, Chen TP, Wen CK, Hung CH, Chen CY, et al. (2007) Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 213: 412–419.
[16]
Cirincione R, Lintas C, Conte D, Mariani L, Roz L, et al. (2006) Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 118: 1248–1253.
[17]
Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, et al. (2003) Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153–160.
[18]
Yang ZH, Cai YY, Sun LH (2005).Promoter hypermethylation of 11 tumor-related genes in non-small cel lung cancer. J Clin Inter Med, 22: , 708–10.
[19]
Zhang Y, Wang R, Song H, Huang G, Yi J, et al. (2011) Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303: 21–28.
[20]
Hu HL,Wang L,Chen SH (2011) Detection and clinical significance of RAR-beta gene methylation in plasma of no-small cell lung cancer patients. Chin J Clin Oncol, 38: ,890–893.
[21]
Zhao XD, Xue SL, Jin YT (2011) The detection and clinical implication of methylation of RAR-beta gene in patients with non-small cell lung cancer. Acta Universitatis Medicinalis Anhui 46: 409–411.
[22]
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
[23]
Lou J, Xue J, Lin Q (2011) Transcriptome-wide network analysis of squamous lung cancer reveals potential methylation genes. Asian Pac J Cancer Prev 12: 2349–2352.
[24]
Gu J, Wen Y, Zhu S, Hua F, Zhao H, et al. (2013) Association between P(16INK4a) promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One 8: e60107.
